B-cell lymphomas diffuse large

Coiffer B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med 2002, 346 235-242. 

Alizedah AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 503-511. 

Diffuse large B-cell lymphomas are the most common lymphoma in patients of all ages but most commonly seen in the seventh decade. Extranodal disease is present at diagnosis in 30% to 40% of patients. The International Prognostic Index score correlates with prognosis. Diffuse aggressive lymphomas are sensitive to chemotherapy with cure achieved in some patients. 

Early-Stage Diffuse Large B-Cell Lymphoma... 

Alizadeh, A.A., et al., "Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling," Nature, 403, 503-511 (2000). 

Coiffier, B., Rituximab in the treatment of diffuse large B-cell lymphomas, Semin. Oncol., 29(Suppl. 2), 30-35, 2002. 

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, et al. 2004. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 1828. 

Robertson Ml, Kahl BS, Vose JM, de Vos S, LaughUn M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 1741-1746. 

Stasik Cl, Nitta H, Zhang W et al (2010) Increased MTC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 95 597-603... 

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouab-dallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma a study by the Groupe d Etude des Lymphomes de I Adulte. J Clin Oncol 2005 23 4117-26. 

M. Q. Huang, D. S. Nelson, S. Pickup, H. Qiao, E. J. DeUkatny, H. Poptani and J. D. Glickson, In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by H and P MRS. Acad. Radiol., 2007,14, 1531-1539. 

A major breakthrough in the treatment of lymphoid malignancies was the discovery of monoclonal antibody activity, especially that of rituximab. Rituximab was the first monoclonal antibody approved by the U.S., FDA for the treatment of relapsed follicular lymphoma (1), and it has now been extensively used for the treatment of various lymphoid neoplasm which express CD20 antigen. Its efficacy has been also demonstrated against diffuse large B-cell lymphoma when administered as a combination regimen such as rituximab plus CHOP (R-CHOP) chemotherapy (2). 

This chapter reviews our current understanding of the mechanism of action of monoclonal antibody (especially rituximab), as well as the role of Fey receptor and Fey receptor gene polymorphisms, and their impact on treatment outcomes in hematologic malignancies including follicular lymphoma (FL), diffuse large B-cell lymphoma (DL-BCL), Waldenstrom s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL). 

The introduction of rituximab plus CHOP chemotherapy (R-CHOP) has significantly improved the treatment outcome of diffuse large B-cell lymphoma (DLBCL) (57). The benefit of R-CHOP therapy has been demonstrated in a randomized trial of R-CHOP versus CHOP in elderly patients with DLBCL (57). It has been proposed that the impact of R-CHOP on the outcomes for DLBCL may be derived from overcoming bcI-2 mediated chemoresistance (58). 

Kim DH, Jung FID, Kim JG et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood2006 108 2720-2725. 

Rosenwald A, Wright G, Chan WC et al Lymphoma/ eukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl JMed 2002 346 1937-1947. 

T.M. and Rimsza, L.M. (2007) Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab. Invest.,... 

B5. Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A. P., Morgan, G. L, and Jack, A. S., Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99,1136-1143 (2002). 

H8. Harada, S., Suzuki, R., Uehira, K., Yatabe, Y., Kagami, Y., Ogura, M., Suzuki, H., Oyama, A., Kodera, Y., Ueda, R., Morishima, Y., Nakamura, S., and Seto, M., Molecular and immunological dissection of diffuse large B cell lymphoma CD5+, and CD5— with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13, 1441—1447 (1999). 

K9. King, B. E., Chen, C., Locker, J., Kant, J., Okuyama, K., Falini, B., and Swerdlow, S. H., Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod. Pathol. 13, 1219-1231 (2000). 

Ml3. Matolcsy, A., Chadbum, A., and Knowles, D. M., De novo CD5-positiveand Richter s syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am. J. Pathol. 147,207-216... 

M27. Monni, O., Joensuu, H., Franssila, K., Klefstrom, J., Alitalo, K., and Knuutila, S., BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90, 1168-1174(1997). 

Skinnider, B. E, Horsman, D. E., Dupuis, B., and Gascoyne, R. D., Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma Correlation with 3q27 and 18q21 chromosomal abnormalities. Hum. Pathol. 30, 803-808 (1999). 

U1. Uherova, P., Ross, C. W., Schnitzer, B., Singleton, T. P., and Finn, W. G., The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am. J. Clin. Pathol. 115,582-588 (2001). 

---